Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically established coronary artery disease or carotid artery disease with greater than 15% stenosis by ultrasound~* Family history of cardiovascular disease~* Apolipoprotein B level greater than or equal to 120 mg/dL (LDL level should be between 100 and 190 mg/dL without medication)~* Has been undergoing lipid therapy for no more than 12 months before study entry~* Medically stable~* Medically able to undergo MRI procedure~Exclusion Criteria:~* Uses pacemaker or has metallic implants~* Has immediate plans for carotid endarterectomy~* History of alcohol or drug abuse~* Active liver disease or liver dysfunction, defined by elevations in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal~* Serum creatine kinase (CK) level greater than 3 times the upper limit of normal before study entry~* Serum creatinine level greater than 2.5 times the upper limit of normal~* Diabetes, with a fasting glucose level greater than 150 mg/dL or hemoglobin A1c (HbA1c) level greater than 8% before study entry~* Uncontrolled high blood pressure, defined as average resting systolic blood pressure greater than 200 mm Hg or average resting diastolic blood pressure greater than 95 mm Hg

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 - single therapy group (Type: ACTIVE_COMPARATOR): Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
- 2 - double therapy group (Type: EXPERIMENTAL): Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
- 3 - triple therapy group (Type: EXPERIMENTAL): Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group

Based on this trial design, predict the completion outcome and termination type (if applicable).